Recent Insights into the Management of Behçet Syndrome
Yesim Ozguler, Ayse Ozdede, Gulen Hatemi Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyCorrespondence: Gulen HatemiIstanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, D...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/634233baf6474120be18e3672eced3ae |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:634233baf6474120be18e3672eced3ae |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:634233baf6474120be18e3672eced3ae2021-12-02T16:27:21ZRecent Insights into the Management of Behçet Syndrome1178-7031https://doaj.org/article/634233baf6474120be18e3672eced3ae2021-07-01T00:00:00Zhttps://www.dovepress.com/recent-insights-into-the-management-of-behet-syndrome-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Yesim Ozguler, Ayse Ozdede, Gulen Hatemi Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyCorrespondence: Gulen HatemiIstanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyTel +902124143000/ 21793Email gulenhatemi@yahoo.comAbstract: Behçet syndrome (BS) is a multisystem vasculitis with variable vessel involvement that shows significant heterogeneity among patients in terms of clinical manifestations and disease course. Treatment choice and response are both influenced by this heterogeneity. BS treatments’ main goals are to quickly suppress inflammatory exacerbations and prevent relapses in order to protect organ functions and provide good quality of life. Besides the long-term experience with steroids and traditional immunosuppressives, biologic drugs, especially TNF inhibitors, have gained increasing importance in the treatment of BS over the years. In this review, we aimed to give an overview of the studies with conventional and biological drugs with proven efficacy in the treatment of BS, as well as promising drugs and current management strategies according to clinical phenotypes.Keywords: Behçet syndrome, treatment, management, biologic agents, TNF inhibitorOzguler YOzdede AHatemi GDove Medical Pressarticlebehçet syndrometreatmentmanagementbiologic agentstnf inhibitorPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 3429-3441 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
behçet syndrome treatment management biologic agents tnf inhibitor Pathology RB1-214 Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
behçet syndrome treatment management biologic agents tnf inhibitor Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Ozguler Y Ozdede A Hatemi G Recent Insights into the Management of Behçet Syndrome |
| description |
Yesim Ozguler, Ayse Ozdede, Gulen Hatemi Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyCorrespondence: Gulen HatemiIstanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology and Behçet Disease Research Center, Istanbul, TurkeyTel +902124143000/ 21793Email gulenhatemi@yahoo.comAbstract: Behçet syndrome (BS) is a multisystem vasculitis with variable vessel involvement that shows significant heterogeneity among patients in terms of clinical manifestations and disease course. Treatment choice and response are both influenced by this heterogeneity. BS treatments’ main goals are to quickly suppress inflammatory exacerbations and prevent relapses in order to protect organ functions and provide good quality of life. Besides the long-term experience with steroids and traditional immunosuppressives, biologic drugs, especially TNF inhibitors, have gained increasing importance in the treatment of BS over the years. In this review, we aimed to give an overview of the studies with conventional and biological drugs with proven efficacy in the treatment of BS, as well as promising drugs and current management strategies according to clinical phenotypes.Keywords: Behçet syndrome, treatment, management, biologic agents, TNF inhibitor |
| format |
article |
| author |
Ozguler Y Ozdede A Hatemi G |
| author_facet |
Ozguler Y Ozdede A Hatemi G |
| author_sort |
Ozguler Y |
| title |
Recent Insights into the Management of Behçet Syndrome |
| title_short |
Recent Insights into the Management of Behçet Syndrome |
| title_full |
Recent Insights into the Management of Behçet Syndrome |
| title_fullStr |
Recent Insights into the Management of Behçet Syndrome |
| title_full_unstemmed |
Recent Insights into the Management of Behçet Syndrome |
| title_sort |
recent insights into the management of behçet syndrome |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/634233baf6474120be18e3672eced3ae |
| work_keys_str_mv |
AT ozgulery recentinsightsintothemanagementofbehccediletsyndrome AT ozdedea recentinsightsintothemanagementofbehccediletsyndrome AT hatemig recentinsightsintothemanagementofbehccediletsyndrome |
| _version_ |
1718383993453281280 |